Clinical significance of elevated antinuclear antibodies in patients with diffuse large B-cell lymphoma: A single center study
Clinical significance of elevated antinuclear antibodies in patients with diffuse large B-cell lymphoma: A single center study
复制标题
DOI：
10.4103/0973-1482.183559
复制
发表时间：
2018-01-01
影响因子：
1.3
通讯作者：
Sun, Hui
中科院分区：
文献类型：
--
作者：
Lang, Junyuan;Ma, Kai;Sun, Hui
目的：为探讨抗核自身抗体（ANA）在弥漫性大B细胞淋巴瘤（DLBCL）诊断和预后评估中的价值，选取2005 - 2014年在晋城市大医医院血液科住院的DLBCL患者82例，健康对照120例。我们检测了82例不同Ann-Arbor分期的DLBCL患者血清中ANA的表达（I期15例，II期22例，III期27例，IV期18例）。结果：DLBCL组ANA阳性率明显高于对照组（P < 0.001），DLBCL组ANA阳性率为30.5%，对照组ANA阳性率为7.5%。然而，大多数检测到ANA的DLBCL患者没有发生自身免疫性疾病，这表明DLBCL中的ANA可能与自身免疫性疾病无关。ANA的表达与DLBCL的临床分期无关。结论：ANA在DLBCL患者中可能是一个与分期无关的预后因素，而不是自身免疫性疾病的指征，并可能代表一种有效的肿瘤免疫应答。
Objective: To investigate the potential diagnostic and prognostic values of antinuclear autoantibodies (ANAs) in diffuse large B-cell lymphoma (DLBCL).Materials and Methods: Eighty-two DLBCL patients and 120 healthy controls were selected from the Department of Hematology, Jincheng Dayi Hospital between 2005 and 2014. We examined the expression of ANA in the sera of the 82 DLBCL patients at different Ann-Arbor stages (15 at Stage I, 22 at Stage II, 27 at Stage III, and 18 at Stage IV). ANA detection was performed by immunofluorescence, and the results were confirmed by Western blotting analysis.Result: ANAs were more frequently detected in DLBCL patients than in controls (P < 0.001), with 25 (30.5%) DLBCL patients and 9 (7.5%) controls displaying elevated ANA levels. However, the majority of DLBCL patients in which ANA were detected did not develop autoimmune diseases, suggesting that ANA in DLBCL might not be correlated autoimmune diseases. Furthermore, no correlation was observed between the expression of ANA and the clinical stages of DLBCL. However, ANA-positive DLBCL patients had a better survival rate (P < 0.05).Conclusions: ANA in DLBCL may be a stage-independent prognostic factor rather than an indication for autoimmune diseases and may represent an effective immune response to the tumor.